Bristol-Myers Squibb Company (NYSE:BMY) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next fireside chat. And again, thanks, everyone, for your attendance. Really do appreciate it. I know the firm appreciates it as well. We have the pleasure of hosting Bristol and its CFO, David Elkins. David, thanks so much for joining us. Why don't I hand it to you for some brief introductory remarks, and then we'll ...

On October 31, Bristol-Myers Squibb (NYSE: BMY ) released financial results for the third quarter of 2024 , which not only beat Wall Street analysts' expectations by a wide margin but also pleasantly surprised me.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceu ...

PHILADELPHIA, PENNSYLVANIA - NOVEMBER 07: Allyson McMillan-Youngblood, SVP U.S. Oncology, Bristol ... [+] Myers Squibb & Board Member, Pennsylvania Conference for Women speaks on stage during 2024 Pennsylvania Conference For Women at Pennsylvania Convention Center on November 07, 2024 in Philadelphia, Pennsylvania. (Photo by Marla Aufmuth/Getty Images for Pennsylvania Conference For Women )Getty Images for Pennsylvania Conference For WomenBristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November ...

Bristol-Myers Squibb Company (NYSE:BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us. To my immediate right is, Samit Hirawat. He is the Chief Medi ...

Bristol Myers Squibb Company (BMY) touched a 52-week high of $56.8 on Nov. 6.  The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months, regaining its lost territories and giving anxious investors a ray of hope.Shares of BMY have risen 20.1% in the past six months compared with the industry’s growth of 5.3%. The stock has also outperformed the sector and the S&P 500 during this period.On Oct. 31, Bristol-Myers reported better-than-expected third-quart ...

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve’s interest rate cuts in September. According to GlobalData, the top 20 global biopharmaceutical companies saw a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. This rebound highlights the industry’s potential for growth despite challenges earlier in the year.Bristol-Myers Sq ...

29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) ... [+] is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria). Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesBristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies that delivered solid earnings reports.   Merck & Co. Inc. NYSE: MRK and The Bristol-Myers Squibb Co. NYSE: BMY beat analysts' estimates on the top and bottom lines. Revenue for both companies was higher than in the same quarter in 2023, but both companies reported lighter year-over-year earnings. For Bristol-Mye ...

Bristol-Myers Squibb Company (BMY) reported adjusted earnings per share (EPS) of $1.80 for the third quarter of 2024, which beat the Zacks Consensus Estimate of $1.49.  In the year-ago quarter, BMY had posted an adjusted EPS of $2.Total revenues of $11.9 billion surpassed the Zacks Consensus Estimate of $11.3 billion. The top line also increased 8% from the year-ago period’s level, primarily driven by a strong growth portfolio and an increase in Eliquis sales.BMY’s shares are trading up following the result ...

Bristol-Myers Squibb Company (NYSE:BMY) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Chris Schott - JPMorga ...